{"ModuleTitle": "Company Description", "CompanyName": "Curis, Inc.", "Symbol": "CRIS", "Address": "128 SPRING STREET BUILDING C, SUITE 500, LEXINGTON, Massachusetts, 02421, United States of America", "Phone": "617-503-6500", "Industry": "Biotechnology: Biological Products (No Diagnostic Substances)", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biotechnology company focused on the development of first-in-class and\r\ninnovative therapeutics for the treatment of cancer. Our clinical stage drug\r\ncandidates are:\r\n*      CA-4948, which is being tested in a Phase 1 dose escalating clinical trial\r\n       in patients with non-Hodgkin lymphomas, including those with Myeloid      \r\n       Differentiation Primary Response Protein 88, or MYD88 alterations. We     \r\n       reported preliminary clinical data from the study in December 2019. We are\r\n       currently planning to initiate a separate Phase 1 trial for acute myeloid \r\n       leukemia and myelodysplastic syndromes patients in the first half of 2020.\r\n\r\n\r\n*      CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig     \r\n       suppressor of T cell activation, or VISTA signaling pathway, which we plan\r\n       to begin clinical testing in a Phase 1a/1b trial in 2020.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f19%2f0001108205-20-000003.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "James E. Dentzer", "title": "President, Chief Executive Officer & Director"}, {"name": "Reinhard von Roemeling", "title": "Senior Vice President-Clinical Development"}, {"name": "Robert E. Martell", "title": "Head-Research & Development"}, {"name": "William E. Steinkrauss", "title": "Chief Financial Officer & Treasurer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}